SCHEMBL24569376

SCHEMBL24569376

Brc1ccc2ncnc(Nc3ccc(Cc4ccn5ncnc5c4)cc3)c2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
ALK Q9UM73 1/20 0.53
ALDH1A1 P00352 1/20 0.53
LMNA P02545 1/20 0.53
GLA P06280 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
NPC1 O15118 2/20 0.50
NCOA1 Q15788 1/20 0.50
NCOA3 Q9Y6Q9 1/20 0.50
MAPT P10636 3/20 0.48
HTT P42858 3/20 0.48
MAPK1 P28482 2/20 0.48
AHR P35869 1/20 0.48
EGFR P00533 7/20 0.47
ERBB2 P04626 2/20 0.46
PRNP P04156 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24167293 0.90 EGFR (0.52) EGFRERBB2NQO2FECHMYH14
SCHEMBL24569385 0.86 EGFR (0.49) KDM4EMEN1KMT2AALKALDH1A1
SCHEMBL24168089 0.84 ALK (0.58) MEN1KMT2AALKALDH1A1L3MBTL1
SCHEMBL24167891 0.81 EGFR (0.54) EGFRERBB2
SCHEMBL24767919 0.80 EGFR (0.47) KDM4EMEN1KMT2AALDH1A1LMNA
SCHEMBL24167454 0.79 EGFR (0.41) KDM4EALDH1A1LMNANPC1NCOA1
SCHEMBL24569380 0.79 EGFR (0.39) MAPTHTTMAPK1AHREGFR
Hydrochloric Acid SCHEMBL8933828 0.79 KDM4E (0.64) KDM4EMEN1KMT2AALKALDH1A1
SCHEMBL24168088 0.79 EGFR (0.53) EGFRERBB2
SCHEMBL24569870 0.77 HTT (0.55) KDM4EALDH1A1LMNANCOA1NCOA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022140769-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN THERAPEUTICS, INC. (US) 2022-06-30 WO disclosed